Oil prices rebound sharply on smaller-than-feared OPEC+ output hike
Masimo Corporation (NASDAQ:{{16565|MAMASI), a global medical technology company valued at $9.69 billion, has reached a new 52-week high, with its stock price climbing to $183.18. According to InvestingPro analysis, the company maintains a GOOD financial health score, though current valuations suggest the stock may be trading above its Fair Value. This milestone reflects a significant uptrend in the company’s market performance, with InvestingPro data showing an impressive 47.74% surge over the past six months alone. Investors have shown growing confidence in Masimo’s innovative product line and strong financial health, as the company continues to expand its presence in the healthcare sector. The stock’s P/E ratio of 121 reflects high growth expectations from investors. The 52-week high serves as a testament to Masimo’s resilience and strategic growth initiatives, which have consistently driven shareholder value amidst a dynamic market landscape. Discover 12 additional key insights about MASI with a comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, Masimo Corporation reported preliminary fourth-quarter sales of $601 million, exceeding the consensus estimate of $591 million and marking a 9% growth on a constant currency basis. For 2024, the company anticipates total revenue of approximately $2.094 billion, reflecting a 2% year-over-year increase. Masimo also provided guidance for 2025, projecting healthcare revenue to be between $1.50 billion and $1.53 billion, surpassing the consensus estimate of $1.442 billion. Analyst Matthew Taylor from Jefferies raised Masimo’s price target to $165 from $145, while maintaining a Hold rating, citing the company’s improved financial outlook. Meanwhile, Needham also reiterated a Hold rating, noting that Masimo’s fourth-quarter revenue exceeded expectations.
Additionally, Masimo announced the immediate termination of Executive Vice President Tom McClenahan, with no successor named yet. The company also disclosed the upcoming resignation of board member Robert Chapek, effective at the 2025 annual meeting. These executive changes have been communicated through regulatory filings, ensuring transparency for investors and stakeholders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.